domains/health/AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics.md

@@ -15,6 +15,12 @@ Insilico Medicine achieved the most significant milestone: positive Phase IIa re
 
 The critical question is whether AI can move the needle beyond Phase I. The pharmaceutical industry's overall ~90% clinical failure rate has not demonstrably changed. "Faster to clinic" is proven; "more likely to work in patients" is not. If AI cracks later-stage success rates, the economic impact dwarfs everything else in healthcare -- a single percentage point improvement in Phase II/III success is worth billions. But the proof is still ahead of us.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+Smith 2026 provides concrete evidence of compression magnitude: Ginkgo Bioworks + GPT-5 compressed 150 years of protein engineering into weeks. This is consistent with Amodei's 10-20x prediction (50-100 years → 5-10 years) and confirms that discovery-phase compression is already happening at scale, not speculative.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -107,6 +107,12 @@ Value in Health modeling study shows Medicare saves $715M over 10 years with com
 
 Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' claim may only apply to short-term payers, while long-term risk-bearers see net savings.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-03-19-glp1-price-compression-international-generics-claim-challenge]] | Added: 2026-03-19*
+
+International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -89,6 +89,12 @@ Weight regain data shows that even among patients who complete treatment, GLP-1
 
 Aon data shows the 80%+ adherent cohort captures dramatically stronger cost reductions (9 percentage points lower for diabetes, 7 points for weight loss), confirming that adherence is the binding variable for economic viability. The adherence-dependent savings pattern means low persistence rates eliminate cost-effectiveness even when clinical benefits exist.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+GLP-1 behavioral adherence failures demonstrate that even breakthrough pharmacology cannot overcome behavioral determinants: patients on GLP-1 alone show same weight regain as placebo without behavior change. This is direct evidence that the 'human constraints' factor (Amodei framework) limits pharmaceutical efficacy independent of drug quality.
+
 ---
 
 Relevant Notes:

domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md

@@ -19,6 +19,12 @@ These findings create a genuine paradox for clinical AI deployment. The system d
 
 Wachter frames the challenge directly: "Humans suck at remaining vigilant over time in the face of an AI tool." The Tesla parallel is apt -- a system called "self-driving" that requires constant human attention produces 100+ fatalities from the predictable failure of that attention. Healthcare's "physician-in-the-loop" model faces the same fundamental human factors constraint.
 
+
+### Additional Evidence (extend)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+AI-accelerated biology creates a NEW health risk pathway not in the original healthspan constraint framing: clinical deskilling + verification bandwidth erosion. At 20M clinical consultations/month with zero outcomes data and documented deskilling (adenoma detection: 28% → 22% without AI), AI deployment without adequate verification infrastructure degrades the human clinical baseline it's supposed to augment. This extends the healthspan constraint to include AI-induced capacity degradation.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -59,6 +59,12 @@ While social determinants predict health outcomes in observational studies, RCT
 
 The Diabetes Care perspective provides a specific mechanism example: produce prescription programs may improve food security (a social determinant) without improving clinical outcomes (HbA1c, diabetes control) because the causal pathway from social disadvantage to disease is not reversible through single-factor interventions. This demonstrates the 10-20% medical care contribution in practice—addressing one SDOH factor (food access) doesn't overcome the compound effects of poverty, stress, and social disadvantage.
 
+
+### Additional Evidence (confirm)
+*Source: [[2026-03-19-vida-ai-biology-acceleration-healthspan-constraint]] | Added: 2026-03-19*
+
+Amodei's complementary factors framework explicitly identifies 'human constraints' (behavior change, social systems, meaning-making) as a factor that bounds AI returns even in biological science. This provides theoretical grounding for why the 80-90% non-clinical determinants remain unaddressed by AI-accelerated biology—they fall into the 'human constraints' category that AI cannot optimize.
+
 ---
 
 Relevant Notes:

inbox/queue/.extraction-debug/2026-03-19-vida-ai-biology-acceleration-healthspan-constraint.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "ai-accelerated-biology-shifts-healthspan-constraint-composition-toward-behavioral-social-determinants.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "amodei-complementary-factors-framework-predicts-bounded-not-unlimited-ai-health-returns.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "ai-accelerated-biology-shifts-healthspan-constraint-composition-toward-behavioral-social-determinants.md:set_created:2026-03-19",
+      "amodei-complementary-factors-framework-predicts-bounded-not-unlimited-ai-health-returns.md:set_created:2026-03-19"
+    ],
+    "rejections": [
+      "ai-accelerated-biology-shifts-healthspan-constraint-composition-toward-behavioral-social-determinants.md:missing_attribution_extractor",
+      "amodei-complementary-factors-framework-predicts-bounded-not-unlimited-ai-health-returns.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-19"
+}

inbox/queue/.extraction-debug/2026-03-19-vida-clinical-ai-verification-bandwidth-health-risk.json

@@ -0,0 +1,37 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "clinical-ai-deskilling-creates-compounding-verification-bandwidth-collapse-at-population-scale.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "mandatory-ai-practice-drills-are-the-missing-institutional-mechanism-for-clinical-ai-deskilling.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 7,
+    "rejected": 2,
+    "fixes_applied": [
+      "clinical-ai-deskilling-creates-compounding-verification-bandwidth-collapse-at-population-scale.md:set_created:2026-03-19",
+      "clinical-ai-deskilling-creates-compounding-verification-bandwidth-collapse-at-population-scale.md:stripped_wiki_link:human-in-the-loop-clinical-AI-degrades-to-worse-than-AI-alon",
+      "clinical-ai-deskilling-creates-compounding-verification-bandwidth-collapse-at-population-scale.md:stripped_wiki_link:healthcare-AI-regulation-needs-blank-sheet-redesign-because-",
+      "clinical-ai-deskilling-creates-compounding-verification-bandwidth-collapse-at-population-scale.md:stripped_wiki_link:OpenEvidence-became-the-fastest-adopted-clinical-technology-",
+      "mandatory-ai-practice-drills-are-the-missing-institutional-mechanism-for-clinical-ai-deskilling.md:set_created:2026-03-19",
+      "mandatory-ai-practice-drills-are-the-missing-institutional-mechanism-for-clinical-ai-deskilling.md:stripped_wiki_link:human-in-the-loop-clinical-AI-degrades-to-worse-than-AI-alon",
+      "mandatory-ai-practice-drills-are-the-missing-institutional-mechanism-for-clinical-ai-deskilling.md:stripped_wiki_link:healthcare-AI-regulation-needs-blank-sheet-redesign-because-"
+    ],
+    "rejections": [
+      "clinical-ai-deskilling-creates-compounding-verification-bandwidth-collapse-at-population-scale.md:missing_attribution_extractor",
+      "mandatory-ai-practice-drills-are-the-missing-institutional-mechanism-for-clinical-ai-deskilling.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-19"
+}

inbox/queue/2026-03-19-glp1-price-compression-international-generics-claim-challenge.md

@@ -7,10 +7,14 @@ date: 2026-03-19
 domain: health
 secondary_domains: [internet-finance]
 format: synthesis
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, generics, patent-cliff, price-trajectory, cost-effectiveness, kb-claim-challenge, scope-qualification]
 flagged_for_rio: ["GLP-1 price compression changes the investment economics for risk-bearing health plans — shorter time horizon to net savings under capitation"]
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -96,3 +100,14 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego
 WHY ARCHIVED: This is a direct scope challenge to the existing claim. The GLP-1 patent cliff data (GeneOnline) is already in queue but unprocessed; this synthesis connects it to the Aon cost data and makes the scope challenge explicit for the extractor.
 
 EXTRACTION HINT: Don't extract a new claim — update/scope-qualify the existing GLP-1 claim. The extractor should add a `challenged_by` reference and update the claim body with the price trajectory sensitivity analysis.
+
+
+## Key Facts
+- Canada semaglutide patents expired January 4, 2026 with immediate generic filings from Sandoz, Apotex, Teva
+- Brazil and India GLP-1 patent expirations March 2026
+- China has 17+ generic GLP-1 candidates in Phase 3 trials
+- Oral Wegovy launched January 2026 at $149-299/month vs $1,300/month for injectable semaglutide
+- Medicare negotiated semaglutide rate: $245/month
+- US/Europe GLP-1 patents extend to 2031-2032
+- Orforglipron (Lilly non-peptide oral GLP-1) potential approval Q2 2026
+- Amycretin shows 22% weight loss without plateau in trials

inbox/queue/2026-03-19-vida-ai-biology-acceleration-healthspan-constraint.md

@@ -7,11 +7,15 @@ date: 2026-03-19
 domain: health
 secondary_domains: [ai-alignment, grand-strategy]
 format: synthesis
-status: unprocessed
+status: enrichment
 priority: high
 tags: [ai-biology-acceleration, healthspan-constraint, belief-disconfirmation, social-determinants, verification-bandwidth, civilizational-health]
 flagged_for_leo: ["This synthesis directly addresses whether healthspan is civilization's binding constraint in the AI era — Leo's civilizational framework needs to incorporate this compositional shift"]
 flagged_for_theseus: ["The Amodei complementary factors framework (physical world speed, data needs, intrinsic complexity, human constraints, physical laws) explains why AI doesn't eliminate behavioral health constraints — Theseus should evaluate whether this framework holds for superintelligence timelines"]
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -115,3 +119,11 @@ PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcome
 WHY ARCHIVED: Documents the keystone belief disconfirmation search result — Belief 1 survives the AI-acceleration challenge because the 80-90% non-clinical determinants are explicitly excluded from what biology can address, per Amodei's own complementary factors framework.
 
 EXTRACTION HINT: Extract the claim that AI-accelerated biology doesn't change the 80-90%/10-20% split — and that this REINFORCES rather than undermines the importance of non-clinical health infrastructure. The Amodei self-defeat (his framework defeats his own health prediction as sufficient for population health) is the key insight.
+
+
+## Key Facts
+- Ginkgo Bioworks + GPT-5 compressed 150 years of protein engineering into weeks (Smith 2026)
+- Amodei predicts AI will compress 50-100 years of biological progress into 5-10 years
+- Amodei predicts potential lifespan doubling to ~150 years from AI-accelerated biology
+- FDA moving from animal testing to AI models and organ-on-chip (April 2025 roadmap)
+- Aon claims data: AI analysis reveals GLP-1 → 50% ovarian cancer risk reduction in 192K-patient dataset

inbox/queue/2026-03-19-vida-clinical-ai-verification-bandwidth-health-risk.md

@@ -7,10 +7,14 @@ date: 2026-03-19
 domain: health
 secondary_domains: [ai-alignment]
 format: synthesis
-status: unprocessed
+status: null-result
 priority: high
 tags: [clinical-ai, verification-bandwidth, deskilling, openevidence, scale-risk, outcomes-gap, health-ai-safety]
 flagged_for_theseus: ["The verification bandwidth problem in clinical AI is the health-specific instance of Catalini's general Measurability Gap — both should be cross-referenced in the AI safety literature"]
+processed_by: vida
+processed_date: 2026-03-19
+extraction_model: "anthropic/claude-sonnet-4.5"
+extraction_notes: "LLM returned 2 claims, 2 rejected by validator"
 ---
 
 ## Content
@@ -80,3 +84,14 @@ PRIMARY CONNECTION: [[human-in-the-loop clinical AI degrades to worse-than-AI-al
 WHY ARCHIVED: This synthesis identifies a structural mechanism (Catalini Measurability Gap + clinical deskilling + AI scale) that doesn't appear in any individual source but emerges from reading them together. The scale asymmetry at 20M consultations/month makes this a population-health priority, not a clinical curiosity.
 
 EXTRACTION HINT: Extract the compounding risk mechanism as a new claim. Do not extract the individual components (deskilling, benchmark-outcomes gap, etc.) — those already exist in KB. Extract specifically the SCALE MECHANISM that makes them dangerous in combination.
+
+
+## Key Facts
+- OpenEvidence reached 20M clinical consultations per month by January 2026
+- OpenEvidence processed 1M consultations in a single day on March 10, 2026
+- OpenEvidence achieved USMLE 100% benchmark score
+- OpenEvidence valued at $12B as of March 2026
+- OpenEvidence used across 10,000+ hospitals
+- 44% of physicians remain concerned about OpenEvidence accuracy despite heavy use
+- Endoscopists using AI for polyp detection: adenoma detection rate dropped from 28% to 22% when AI was turned off (Hosanagar/Lancet Gastroenterology 2023)
+- Zero peer-reviewed outcomes data for OpenEvidence at 20M consultation/month scale